Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry
J Eur Acad Dermatol Venereol 2025;39:1631–42 https:// doi. org/ 10. 1111/ jdv. 20828
This study by Lluch-Galcerá et al. provides valuable RWE to inform personalized clinical decision-making in the treatment of PsO. Authors evaluated the incidence of MACE associated with each systemic treatment used for patients with PsO and compared these rates to those observed with MTX.
Findings by Lluch-Galcerá et al. suggest a decreased risk of MACE with APR and IL-17, while CYC was associated with an increased risk compared to MTX. The remaining systemic PsO treatments were not significantly associated with an increased risk of MACE. Assessing CVD in PsO patients is crucial, as different treatments can affect MACE incidence differently. Hence, understanding the cardiovascular impact of PsO treatments is essential for improving patient outcomes and reducing overall morbidity and mortality.
Keywords:
